Helix BioPharma Corp.
OTC: HBPCF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Thomas Mehrling
- Employees
- 7
- Headquarters
- Toronto, Canada
- IPO year
- 2009
- Market cap
- $130.6M
- Website
- https://www.helixbiopharma.com
Loading HBPCF…
Loading profile data…Frequently asked questions about HBPCF
What does Helix BioPharma Corp. (HBPCF) do?
Helix BioPharma Corp. is a Canadian enterprise focused on immuno-oncology. The company's research and development efforts include L-DOS47, a drug candidate aimed at treating non-small cell lung cancer, and V-DOS47, which is designed to interact with vascular epithelial growth factor receptor 2 (VEGFR2). Helix has established collaborative agreem...
Where does HBPCF trade?
Helix BioPharma Corp. (HBPCF) trades on the Other OTC.
What sector is HBPCF in?
Helix BioPharma Corp. (HBPCF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Helix BioPharma Corp.?
Thomas Mehrling is the chief executive officer of Helix BioPharma Corp. (HBPCF).
Where is Helix BioPharma Corp. headquartered?
Helix BioPharma Corp. is headquartered in Canada.
Does HBPCF pay a dividend?
Helix BioPharma Corp. (HBPCF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did HBPCF go public?
Helix BioPharma Corp. (HBPCF) completed its initial public offering in 2009.